



**meetings
in a box**

ROAD TO



ESMO 2025

A cura di Alessandro Pastorino, Genova

ACC  MED

ACCADEMIA NAZIONALE DI MEDICINA

Genitourinary cancer

- **KEYNOTE-905/EV 303** - *Neo/adjvant* - EV + Pembro vs cistectomy in platinum ineligible MIBC urothelial carcinoma (**LBA2**)
- **IMvigor011** - *“Adjuvant”* - Atezolizumab vs Plc in ctDNA+ MIBC urothelial carcinoma (pT3T4 or pN+, ypT3-T4 or ypN+) (**LBA8**)
- **RC48-C016** - *First line* - Disitamab Vedotin + Toripalimab vs Plt Gem in HER2 (1+, 2+, 3+) urothelial carcinoma (**LBA7**)
- **PSMAddition** - *First line* - ARSI + ADT + LuPSMA vs ARSI + ADT in mHSPC (not candidate to docetaxel) (**LBA6**)

Breast cancer

- **DB-11** - *Neoadjuvant* - T-Dxd + THP vs ddAC + THP in HER2 positive early stage high-risk (T3-T4 e/o N1-3) (2910)
- **DB-05** - *Adjuvant* - T-Dxd vs TDM-1 in HER2 positive non ypCR (invasive residual) after neoadjuvant TH ± P (LBA1)

Lung cancer

- **HARMONi-6** - *First line* - Platinum-based + Ivonescimab vs Tislelizumab in NSCL-Squamous (any PD-L1) (LBA4)
- **OptiTROP-Lung04** - *Second line (and over)* - Sacit-Tirumotecan vs Plt Pemetrexed in NSCLC-Adeno in PD after iEGFR (LBA5)

Gastrointestinal cancer

- **DYNAMIC-3** - *Adjuvant* - De-escalation of chemotherapy in stage III CRC with ctDNA negative after surgery (**LBA9**)
- **FORTITUDE-101** - *First line* - FOLFOX + Bemarituzumab vs FOLFOX in FGFR2b+ metastatic HER2 negative gastric cancer (**LBA10**)

Gynecological cancer

- **ENGOT-ov65/KEYNOTE-B96** - Paclitaxel + Pembro $\pm$ Bev vs Paclitaxel + Placebo $\pm$ Bev in Plt resistant ovarian cancer (**LBA3**)

Uveal melanoma

- **IMA203 (PRAME-directed T-cell receptor - TCR)** - Previously treated advanced or metastatic uveal melanoma (**1600O**)